Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Wilder

Showing results (11-20 of 197) with videos related to

Pageof 20
Sort By:
JAMA|April 22, 1988
Treatment of the patient with rheumatoid arthritis refractory to standard therapyR L Wilder
Annals of the Rheumatic Diseases|October 16, 2002
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseasesR L Wilder
Molecular Medicine Today|September 4, 1999
Animal models of rheumatoid arthritisB Joe, R L Wilder
Rheumatic Diseases Clinics of North America|November 21, 2000
Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseasesM Cutolo, R L Wilder
Bulletin on the Rheumatic Diseases|August 1, 1992
Neurobiology and inflammatory arthritisJ M Cash, R L Wilder
Rheumatic Diseases Clinics of North America|November 21, 2000
Hormonal alterations in rheumatoid arthritis, including the effects of pregnancyK S Kanik, R L Wilder
Rheumatic Diseases Clinics of North America|February 1, 1995
Refractory rheumatoid arthritis. Therapeutic optionsJ M Cash, R L Wilder
The American Journal of Medicine|August 1, 1987
Cyclosporin A in progressive systemic sclerosisD E Yocum, R L Wilder
Arthritis and Rheumatism|November 1, 1985
Regulation of susceptibility to bacterial cell wall-induced arthritis in ratsR L Wilder, J B Allen
Arthritis and Rheumatism|March 1, 1989
Participation of synovial mast cells in intermittent hydrarthrosisD G Malone, R L Wilder
Pageof 20

Showing results (11-20 of 197) with videos related to

Sort By:
Pageof 20
JAMA|April 22, 1988
Treatment of the patient with rheumatoid arthritis refractory to standard therapyR L Wilder
Annals of the Rheumatic Diseases|October 16, 2002
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseasesR L Wilder
Molecular Medicine Today|September 4, 1999
Animal models of rheumatoid arthritisB Joe, R L Wilder
Rheumatic Diseases Clinics of North America|November 21, 2000
Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseasesM Cutolo, R L Wilder
Bulletin on the Rheumatic Diseases|August 1, 1992
Neurobiology and inflammatory arthritisJ M Cash, R L Wilder
Rheumatic Diseases Clinics of North America|November 21, 2000
Hormonal alterations in rheumatoid arthritis, including the effects of pregnancyK S Kanik, R L Wilder
Rheumatic Diseases Clinics of North America|February 1, 1995
Refractory rheumatoid arthritis. Therapeutic optionsJ M Cash, R L Wilder
The American Journal of Medicine|August 1, 1987
Cyclosporin A in progressive systemic sclerosisD E Yocum, R L Wilder
Arthritis and Rheumatism|November 1, 1985
Regulation of susceptibility to bacterial cell wall-induced arthritis in ratsR L Wilder, J B Allen
Arthritis and Rheumatism|March 1, 1989
Participation of synovial mast cells in intermittent hydrarthrosisD G Malone, R L Wilder
Pageof 20